Tandem Diabetes Care Inc
$ 22.38
19.11%
07 Aug - close price
- Market Cap 1,557,171,000 USD
- Current Price $ 22.38
- High / Low $ 22.65 / 17.07
- Stock P/E N/A
- Book Value 1.93
- EPS -1.63
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.66 %
- 52 Week High 29.65
- 52 Week Low 10.00
About
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$28.23
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-19 | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-02-21 | 2023-11-01 |
| Reported EPS | -0.31 | -0.3 | -0.01 | -0.31 | -0.48 | -0.67 | -0.4356 | -0.36 | -0.48 | -0.64 | -0.27 | -0.38 |
| Estimated EPS | -0.34 | -0.44 | -0.09 | -0.34 | -0.4 | -0.61 | -0.2357 | -0.41 | -0.53 | -0.76 | -0.25 | -0.36 |
| Surprise | 0.03 | 0.14 | 0.08 | 0.03 | -0.08 | -0.06 | -0.1999 | 0.05 | 0.05 | 0.12 | -0.02 | -0.02 |
| Surprise Percentage | 8.8235% | 31.8182% | 88.8889% | 8.8235% | -20% | -9.8361% | -84.8112% | 12.1951% | 9.434% | 15.7895% | -8% | -5.5556% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNDM
2026-08-08 03:10:48
Tandem Diabetes Care's stock surged 19% after its Q2 earnings report, despite a net loss, due to a significant recovery in gross margin to 57%. Revenue grew 6%, and the net loss narrowed by 60%, with strong performance in international pump shipments and an increasing presence in Pharmacy PayGo. While the margin improvement is positive, concerns remain regarding continued losses and capital allocation risks.
2026-08-07 21:10:48
Tandem Diabetes Care Inc (TNDM) reported Q2 2026 financial results, including a loss and lagging revenue estimates, despite some key metrics showing positive movement. The company announced upcoming conference presentations, product compatibility expansions, and plans to release Q2 results in August 2026. This news comes as next-generation diabetes therapies are reshaping healthcare, presenting multi-billion-dollar revenue opportunities in the market.
2026-08-07 21:10:48
Tandem Diabetes Care reported strong second-quarter results with record sales, pump shipments, and gross margin, driven by progress in pharmacy-channel reimbursement and new insulin-delivery technologies. The company saw increased U.S. and international sales, though pharmacy-channel transition created a near-term revenue headwind. Tandem reaffirmed its 2026 financial outlook and provided updates on pipeline developments, including a tubeless feature for the Mobi pump and a new infusion technology.
2026-08-07 21:10:48
Tandem Diabetes Care, Inc. reported strong financial results for Q2 2026, with worldwide sales increasing 6% to $254.6 million and gross margin up 460 basis points to 57%. The company also highlighted strategic achievements, including FDA submissions for Tandem Mobi, expanded global technology solutions, and reaffirmed its full-year 2026 financial guidance for sales between $1.065 billion and $1.085 billion.
2026-08-07 21:10:48
Tandem Diabetes Care, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of -$0.31, which beat estimates by $0.01. The company's revenue for the quarter was $254.56M, representing a 5.77% year-over-year increase, though it missed revenue expectations by $510.18K. The slide deck accompanies their earnings call from August 7, 2026.
2026-08-06 22:10:00
Tandem Diabetes Care (NASDAQ:TNDM) reported record Q2 2026 sales of $255 million, despite a slight miss on revenue forecasts, driven by a strategic transition to a "PayGo" pharmacy-based reimbursement model. This new model is expected to more than double lifetime revenue per patient and improve gross margins. The company reaffirmed its full-year 2026 guidance, projecting sales of $1.065 billion to $1.085 billion, and anticipates significant long-term profitability improvements as the transition progresses.
